Comparison of the effects of angiotensin receptor–neprilysin inhibitors and thiazide diuretic/renin–angiotensin system inhibitor combination therapy in hypertensive patients: a retrospective cohort study

• Published in: Journal of human hypertension 2023-12, Vol.37 (12), p.1049-1055
• Main Authors: Mitsuno, Ryunosuke, Uchiyama, Kiyotaka, Nakayama, Takashin, Takahashi, Rina, Yoshimoto, Norifumi, Yamaguchi, Shintaro, Washida, Naoki, Kanda, Takeshi, Hayashi, Kaori, Itoh, Hiroshi
• Format: Article
• Language: English
• Subjects: 692/699/1585/104; 692/699/75/243; Angiotensin; Antihypertensives; Blood pressure; Body weight; Combination therapy; Diuretics; Epidemiology; Epidermal growth factor receptors; Glomerular filtration rate; Health Administration; Hypertension; Hypertriglyceridemia; Hyperuricemia; Medicine; Medicine & Public Health; Neprilysin; Public Health; Renal function; Renin; Uric acid
• ISSN: 1476-5527; 0950-9240; 1476-5527
• DOI: 10.1038/s41371-023-00851-9

Angiotensin receptor–neprilysin inhibitors (ARNIs) have been approved as antihypertensive agents in Japan, and thiazide diuretics (TZDs) are widely used concomitantly with renin–angiotensin system inhibitors (RASIs) for hypertension. This retrospective study included patients with hypertension who switched from RASI to ARNI therapy (ARNI group) and those who were prescribed TZDs with RASIs (TZD/RASI group). Drug-related changes in the estimated glomerular filtration rate (eGFR), blood pressure (BP), body weight (BW), serum electrolytes, uric acid (UA), and triglyceride levels were compared between the two groups. Overall, 70 participants (31 and 39 in the ARNI and TZD/RASI groups, respectively) were enrolled and observed for a median of 2 months. According to linear mixed models, compared with the TZD/RASI group, the ARNI group exhibited a significant change in mean eGFR of 3.71 mL/min/1.73 m 2 [95% confidence interval (CI), 0.57–6.84; P  = 0.02] from the time of switching drug to the next outpatient visit. Further, compared with the TZD/RASI group, the ARNI group exhibited significant changes in mean serum UA (−1.27; 95% CI, −1.66 to −0.88), sodium (1.22; 95% CI, 0.12 to −2.32), chloride (2.14; 95% CI, 0.75–3.52), and triglyceride (−52.1; 95% CI, −100.9 to −3.29) levels. Conversely, serum potassium levels, BW, and systolic and diastolic BP did not differ significantly between the two groups ( P  = 0.69, 0.44, 0.49, and 0.66, respectively). Compared with the combination therapy of TZD and RASI, ARNI therapy causes less renal dysfunction, hyperuricemia, and hypertriglyceridemia with fewer electrolyte abnormalities and no significant difference in antihypertensive effects.